Signal transduction pathways are intricately fine-tuned to accomplish diverse biological processes. An example is the conserved Ras/mitogen-activated-protein-kinase (MAPK) pathway, which exhibits context-dependent signaling output dynamics and regulation. Here, by altering codon usage as a novel platform to control signaling output, we screened the Drosophila genome for modifiers specific to either weak or strong Ras-driven eye phenotypes. We mapped the underlying gene from one modifier to the ribosomal gene RpS21. RpS21 preferentially influences weak Ras/MAPK signaling outputs, and negatively regulates Ras/MAPK in multiple cell/tissue and signaling settings. In turn, MAPK signaling may regulate its own negative feedback by promoting RpS21 expression. These data show that codon usage manipulation can identify output-specific signaling regulators, and identify RpS21 as an in vivo Ras/MAPK phenotypic regulator.
INTRODUCTION
Conserved signal transduction pathways are employed reiteratively throughout nature during diverse processes such as cell fate decisions and tissue growth. These same pathways can be aberrantly regulated in disease. Large numbers of molecular regulators of these pathways have been identified using high-throughput genetic screening. Additionally, quantitative imaging approaches have revealed intricate signaling regulation. This regulation includes feedback control of the duration or strength of a downstream biochemical signaling output (e.g., weak or strong activation of a target gene). A current challenge is to place the numerous identified signaling pathway regulators in the context of complex signaling dynamics, and to relate such regulation to in vivo signal-dependent processes.
An example of the complexity of signaling regulation is the evolutionarily conserved Ras/mitogen activated protein kinase (MAPK) pathway. In canonical MAPK signaling, receptor tyrosine kinase stimulation converts the Ras GTPase to an active GTP-bound conformation. Ras-GTP then activates the MAPK pathway, comprised of Raf kinases, which are activated by Ras and phosphorylate/active Mek kinases, which do the same to Erk kinases. Through highly successful modifier screen approaches in models such as the Drosophila eye [1] [2] [3] [4] [5] [6] [7] [8] and C. elegans vulva [9] [10] [11] [12] [13] , regulators of this core pathway have been identified. Additional Drosophila cell-based screens using a biochemical MAPK output (Erk phosphorylation) have identified many other Ras/MAPK regulators [14] [15] [16] .
These numerous molecular regulators contribute to a diversity in Ras/MAPK signaling dynamics. Using an optogenetics-driven MAPK activation approach in cultured mammalian cells, it was revealed that distinct Ras/MAPK regulation (such as a paracrine STAT3 circuit) can distinguish between biochemical signaling outputs, namely sustained (strong) or transient (weak) Erk activation by Ras 17 . These biochemical outputs are regulated by negative feedback on Erk 18 . Importantly, in vivo context plays a role in whether a given strength of signaling output leads to a phenotypic output. Specifically, taking a similar optogenetic approach in the early developing fly embryo, it was shown that manipulating Erk activation strength has minimal effects on cells at the poles of the embryo, but has a profound impact on development of cells in the middle of the embryo 19 . Further, expressing an activating mutant of Mek in either Drosophila or zebrafish was recently shown to either activate or repress Erk phosphorylation depending on the cell type and gene expression environment 20 . These observations suggest that distinct Ras/MAPK regulation operates in distinct cellular contexts. Taken together, these studies highlight the need to better understand how distinct Ras/MAPK signaling states (e.g., strong or weak) are controlled by distinct sets of Ras/MAPK molecular regulators, in the context of an in vivo phenotype.
Here, we introduce an approach to genetically screen for signal output-specific regulators of Ras/MAPK signaling. This approach, which should be applicable to any signaling pathway, involves controlling the amount of active Ras protein produced by changing codon usage in the single Drosophila Ras gene 21 (FlyBase: Ras85D, hereafter Ras). Rare codons are wellassociated with poor mRNA translation 22 . We have previously found that changing rare codons in the mammalian Ras isoform KRAS to their common counterparts leads to elevated translation, protein, signaling, and transformation 23 . We report the generation and characterization of transgenic flies and cell lines whereby the amount of active Ras protein produced, the resultant level of Erk activation, and resultant rough-eye phenotype is dictated solely by the codon usage engineered into a given Ras transgene. We then report the use of such transgenic flies to screen a whole genome deficiency (termed Df for convenience) kit for genetic modifiers of eye phenotypes that are specific to only strong or only weak Ras/MAPK signaling. Of the 15 Dfs identified, we successfully mapped the modification of Df(2L)BSC692, an enhancer of the rougheye phenotype driven only by weak Ras/MAPK signaling, to the ribosomal protein S21 gene (RpS21). We show that RpS21 negatively regulates Ras protein levels in several contexts, the effect of which is preferentially manifested at low levels of MAPK signaling. Further, MAPK signaling may also positively regulate RpS21 protein levels, suggesting that RpS21 is potentially part of a negative feedback regulatory mechanism that is most effective under conditions of lowlevel MAPK signaling. This approach highlights the usefulness of codon manipulation as a viable approach to identify signal output-specific signaling regulation.
RESULTS

Exploiting codon usage to control MAPK signaling output
To identify Ras/MAPK molecular regulators that differentially impact strong or weak signaling outputs, we required a platform to tightly control the strength of MAPK signaling. To activate the pathway, we expressed a highly conserved, mutant active (G12V) Drosophila Ras transgene (termed Ras V12 here for convenience). To control MAPK signaling strength during fly development, we opted for the new approach of simply changing the codon usage of a Ras V12 transgene. Codons that occur infrequently in a given genome (rare codons) are known to impede translation, including in Drosophila [24] [25] [26] [27] [28] [29] [30] . By engineering a gene enriched in rare codons for each given amino acid, it is possible to create an mRNA that is poorly translated without altering the amino acid sequence of the encoded protein. This has the distinct advantage that control of protein expression is embedded in the DNA and requires no additional factors or experimental variables. We used established data on Drosophila codon usage (see Methods) and created four distinct versions of Drosophila Ras transgenes: 1) we altered none of the codons (Ras V12 Native), 2) we made all codons the most commonly occurring in the genome (Ras V12 Common), 3) we made all codons the most rare in the genome (Ras V12 Rare), and 4) we created a control wild-type version lacking the V12 mutation and also lacking codon alteration (Ras WT Native). To monitor expression, all four transgenes were epitope-tagged at the N-terminus with a 3XFLAG-tag sequence and expressed under the control of a Gal4-inducible UAS promoter (Fig1a, see Methods). We note that Ras V12 Native has primarily common codons and a similar Codon Adaptive Index (CAI 31 ) to Ras V12 Common 21 , while the CAI for Ras V12 Rare is much lower (FigS1a, b). To control for position effects, all transgenes were integrated at the same site in the genome (see Methods).
As a measure of signaling output strength, we chose to use an in vivo phenotypic readout rather than a biochemical readout, an approach validated by quantitative studies of MAPK activation in Drosophila embryos 19, 20 . For genetic screening of Ras/MAPK phenotypic regulators, the Drosophila eye is a highly accessible model. Driving expression of Ras V12 in the developing eye with an eye-specific promoter such as sevenless (sev) dysregulates the proper differentiation of the R7 photoreceptor cell, leading to an easily scored 'rough-eye' phenotype 32, 33 . This phenotype relies on Ras action through the conserved MAPK pathway 1, 34 .
We first assayed the phenotypic output of each Ras transgene in vivo by driving their expression in the developing fly eye using sevenless (sev)-Gal4. As expected 32 , expression of Ras WT in this manner does not result in a rough-eye phenotype (FigS1c). However, when we expressed the constitutive-active versions of Ras, we found a range of rough-eye phenotypes (Fig1b). We binned these phenotypes into one of three classes: severe, moderate, or mild. Each class was assigned an increasing numeric score (Fig1b, see Methods). We then calculated an average severity score for each Ras transgene. Ras V12 Native and Ras V12 Common animals exhibit a similar phenotypic score, reflecting their similar CAI. Further, this phenotypic score is, on average, approximately 2-fold more severe than that of Ras V12 Rare (Fig1c). To determine whether protein levels track with the difference in rough-eye phenotype, we isolated heads from flies encoding the three active Ras transgenes in triplicate and immunoblotted with an anti-FLAG antibody. Ras V12 protein levels are similar between Ras V12 Native and Ras V12 Common flies, and both are expressed ~2-fold higher than Ras V12 Rare (Fig1d, FigS1d) . Given that Ras V12 Native and Ras V12 Common produce similar levels of protein and have the same rough-eye phenotype, for further experiments we opted to control Ras V12 expression using the Ras V12 Common and Ras V12 Rare transgenes. These experiments established that codon usage can be manipulated to examine an in vivo, Ras signal-driven output (eye phenotype), and identified both weak (Ras V12 Rare) and strong (Ras V12 Common) versions of this output.
To examine the effect of expression of Ras V12 Rare versus Ras V12 Common transgenes on known biochemical outputs of downstream MAPK signaling, we evaluated the level of activated finding that Ras V12 Common is expressed higher and more robustly activates the MAPK pathway compared to Ras V12 Rare (FigS1f). In sum, our findings establish Ras V12 Rare and Ras V12 Common as two distinct transgenes that either weakly or strongly control Ras/MAPK signaling output (as measured by Ras V12 expression and MAPK activation), and that transgene-driven signal strength tracks with an observable difference in phenotypic output.
A genome-wide screen uncovers differential phenotypic regulation between strong and weak Ras/MAPK signaling states
We next sought to use our codon alteration system to gain insight into how the Ras/MAPK pathway can be differentially regulated in different signal-strength states. To do so, we screened for molecular regulators that modify Ras/MAPK phenotypes driven only by strong or only by weak signaling states. We first confirmed that Ras V12 Common and Ras V12 Rare rough-eye phenotypes were both in the range that can be modified. Specifically, heterozygous loss-of-function mutations in two known Ras suppressors, kinase suppressor of ras, or ksr 8 36 . These results establish that codon-altered Ras V12 transgenes are subject to phenotypic modification, including by dose-sensitive haplo-insufficient mutations.
Previous modifier screens, including in the eye, employed the native Ras cDNA to express activated Ras 1, 7, 33, 37 . This sequence has a strong common-codon bias (FigS1b), and is similar to Ras V12 Common in terms of MAPK biochemical and phenotypic outputs (Fig1). To find unidentified modifiers that may be specific to weaker (or stronger) MAPK-driven phenotypes, we conducted a genome-wide unbiased haplo-insufficiency screen to specifically identify modifiers of the rougheye phenotype driven by only Ras V12 Rare, (or only Ras V12 Common), (Fig2a). We used the Bloomington Deficiency (Df) Kit, which covers 98.3% of the euchromatic genome 38 . In a primary screen (Fig2b, TableS1), we crossed 470 Dfs representing 99.1% of the Df collection to animals with Ras V12 Rare or Ras V12 Common expressed in the eye by sev-Gal4, and scored the resulting eye severity in an average of 30 (Ras V12 Common) or 60 (Ras V12 Rare) progeny animals per cross.
We also factored animal lethality into our scoring (see Methods).
As expected, we found general Ras modifiers that either enhance or suppress eye phenotypes driven by both Ras V12 transgenes (Fig2c, d, TableS1 ). Interestingly, we identified more enhancers than suppressors (16% versus 7%, Fig2c). The reason for this remains to be determined, but we note that our calculation of phenotypic modification (see Methods) included scoring animal lethality, which may identify strong enhancers of Ras V12 Common not identified in previous screens based solely on a rough-eye phenotype. Of great interest, we also identified Dfs whereby Ras V12 Common and Ras V12 Rare are differentially modified (Fig2a), meaning they scored as only modifying the eye phenotype driven by a single signaling state (Ras V12 Common or Ras V12 Rare, not both). Using a low-stringency cutoff score (see Methods), we identified 178 putative differential modifier Dfs in our primary screen (Fig2b, TableS1). These Dfs were then re-tested in a secondary screen (Fig2b) by crossing them a second time to sev-Ras V12 Common and sev-Ras V12 Rare. In this screen, we used a more stringent cutoff score to define a differential modifier (see Methods). This scoring and replicate analysis reduced the number of candidates to 15 Dfs, or 3% of the tested Dfs (Fig2c, d, TableS1) , that reproducibly differentially modify either only Ras V12 Common or only Ras V12 Rare (Fig3a). Among these differential modifiers, we again recovered more enhancers than suppressors, although importantly we recovered both enhancers of Ras V12 Common and suppressors of Ras V12 Rare, arguing that our screen had the dynamic range to modify both strong (Ras V12 Common) and weak (Ras V12 Rare) Ras/MAPK signaling outputs (Fig3b).
We next queried both the general (signal output-independent) and differential (signal outputdependent) modifiers against a FlyBase database of all reported Ras genetic enhancers and suppressors (see Methods). 56% of our general modifier Dfs covered regions of the genome containing reported Ras enhancers or suppressors, validating our approach. Additionally, we note that among our identified differential modifier Dfs, most (73%) do not encompass known Ras modifiers, supporting the idea that our signal strength-specific modifier hits are enriched in new Ras enhancers and suppressors (Fig3c). To explore possible relationships amongst these 15 differential modifier Dfs, we queried the genes within differential versus enhancer and suppressor Dfs against the established list of FlyBase Gene Groups (FBGG). Interestingly, the gene groups enriched in the differential Dfs do not overlap with those in the general enhancer/suppressor Dfs (Fig3d), suggesting that the differential modifiers may represent a distinct class of Ras modifiers.
Unlike the general modifier Dfs, differential modifier regions are enriched for basic Helix Loop Helix (bHLH) transcription factors, potentially reinforcing their distinct regulation of Ras/MAPK signaling. In summary, by controlling Ras/MAPK signal output strength through codon usage and using a phenotypic output screen, we successfully identified Dfs that alter a Ras/MAPK phenotype in a signaling output-specific fashion.
RpS21 negatively regulates Ras/MAPK signaling in a signal strength-specific manner
To identify a differential modifier at the single gene level, we focused on Df(2L)BSC692 as it was one of the smallest deficiencies, encompassing only 12 genes, that specifically enhanced FigS3a) . Of these 12 genes, Ribosomal protein S21, or RpS21 (also known as overgrown hematopoietic organs 23B/oho23B), represented a plausible candidate modifier.
RpS21 stands out among small ribosomal subunits for its reported negative regulation of hematopoietic and imaginal disc hyperplasia 39 . To determine if RpS21 was the responsible gene in Df(2L)BSC692 for specifically enhancing Ras V12 Rare, we assessed the rough-eye phenotype of Ras V12 Common and Ras V12 Rare in the background of the mutant RpS21 0375 . Indeed, only the sev-Ras V12 Rare rough-eye phenotype is enhanced in the RpS21 0375 /+ background (Fig4a). To test whether other ribosomal subunits may also be involved in Ras/MAPK regulation, we conducted a screen using available heterozygous mutants and RNAi constructs for 15 other small ribosomal subunits. Where possible, we used multiple alleles/RNAi constructs. Of these, at least one allele/RNAi for 4 other subunits also scored as differential (signal-strength specific) Ras/MAPK modifiers in the eye, including mutants for 3 genes that, like RpS21 scored as enhancers of Ras V12 Rare but not Ras V12 Common (TableS2). Together, these findings identify RpS21 as the responsible modifier in one Df from our signal strength-specific screen, and also implicate at least a subset of other ribosomal subunits in signal strength-dependent Ras/MAPK regulation.
Given the identification of both an RpS21 mutant allele and a small deficiency encompassing this gene (Df(2L)BSC692) as a differential Ras V12 modifier, we next turned our attention to the underlying mechanism of this phenotype. To this end, we measured the level of Ras V12 and p-Erk by immunoblot analysis in four completely distinct settings: ectopic signaling in adult fly heads, ectopic signaling in cultured S2 cells, endogenous signaling in cultured serum-stimulated KC cells, and endogenous signaling in adult fly ovaries. Our results overall closely matched our genetic evidence of a negative regulation of Ras levels and MAPK signaling by RpS21. As in the eye, we found this negative regulation to preferentially impact weak Ras/MAPK signaling.
In the heads of Ras V12 Rare flies, both transgenic Ras protein and MAPK signaling levels increase in RpS21/+ animals relative to wild type. However, unlike our lack of an observable phenotypic enhancement of Ras V12 Common in the eye, at the biochemical output level we also observe an increase in the level of Ras V12 Common and MAPK signaling in the RpS21 0375 /+ background (Fig4b, FigS3b) . This result shows that RpS21 also modifies Ras V12 Common protein levels, but that only modification of Ras V12 Rare protein by RpS21 leads to an observable phenotypic output. Next, we examined S2 cells transduced with an expression vector encoding either Ras V12 Common versus Ras V12 Rare and used RNAi to reduce RpS21 levels. Consistent with our mutant analysis in animals, RNAi reduction of RpS21 also elevates Ras V12 Rare levels and MAPK signaling in Ras V12 Rare cells. As in our fly eye analysis, we did not observe an effect of RpS21 reduction on Ras/MAPK pathway protein levels or activation in Ras V12 Common cells.
We note that relative to Ras V12 Rare S2 cells, the level of Ras V12 protein and MAPK signaling are Our immunoblot analysis validates our genetic screen finding that RpS21 can act to negatively regulate MAPK signaling, in a manner that potentially depends on the strength of Ras/MAPK signaling. One interpretation of these data is that RpS21 has a minimal effect on MAPK signaling output above a certain threshold of MAPK signaling. Such a model would predict that experimentally reducing the amount of Ras V12 Common expression should render fly eye development sensitive to the RpS21 0375 /+ mutant background. To experimentally test this threshold model, we took advantage of the well-known fact that expression of transgenes using the Gal4-UAS system is responsive to temperature, with higher temperature resulting in higher expression over the physiological range of 18°C-29°C. In agreement, increasing temperature from 18°C to 29°C causes an observable and significant increase in the phenotypic severity of Ras V12 Common (and Ras V12 Native), but has little effect on Ras V12 Rare (FigS3e). These results showed that we could potentially use temperature to test a signaling threshold model. We thus evaluated the rough-eye phenotype of sev-Ras V12 Common versus sev-Ras V12 Rare flies in a wildtype versus RpS21 0375 /+ mutant background, only this time at 18°C. At this lower temperature, RpS21/+ now acts as an enhancer of Ras V12 Common (Fig4e) . Interestingly, RpS21/+ no longer enhances Ras V12 Rare, underscoring the sensitivity of RpS21/+ to Ras/MAPK signaling strength.
Collectively, these results demonstrate that while RpS21 negatively regulates Ras-MAPK signaling in diverse contexts, at the phenotypic level this regulation preferentially impacts low level Ras/MAPK signaling.
MAPK signaling can promote RpS21 expression
The MAPK pathway is known to control expression of its negative regulators, which can provide pathway feedback regualtion [42] [43] [44] . Further, Drosophila Ras/MAPK signaling was recently shown to regulate rRNA synthesis and ribosome biogenesis 45 . To investigate whether RpS21 can be similarly regulated by the MAPK pathway, we compared the level of RpS21 protein when this pathway was activated in S2 cells by expression of activated Mek EE , Ras V12 , or Raf ED . All three forms of activating the MAPK pathway elevate levels of RpS21 (Fig5a,b, FigS4a,b) . We validated these results in the opposite direction, namely demonstrating that the high levels of RpS21 induced by Ras V12 Common or Ras V12 Rare in KC cells is reduced by treatment with the Mek inhibitor Trametinib (Fig5c, FigS4c) . In vivo, RpS21 levels are higher in heads of sev-Ras V12 Common compared to sev-Ras V12 Rare flies (Fig5d, FigS3d) , again consistent with a positive relationship between MAPK activation and RpS21 levels.
The above results suggest that, as Ras/MAPK activation rises, so will RpS21 levels, which will then feedback to inhibit Ras/MAPK activation. To test this idea, we took advantage of our serum re-addition model in KC cells to explore the relationship of endogenous MAPK signaling and RpS21 levels in a temporal manner. We thus examined the amount of RpS21 expressed by immunoblot analysis when the MAPK pathway was stimulated in serum-starved KC cells by the addition of serum, as above. As expected, addition of serum causes a rapid increase in p-Mek followed by p-Erk levels, which is mirrored by a rapid increase in RpS21 levels (Fig5e, FigS4e) .
These results are consistent with our findings that the MAPK pathway stimulates RpS21 expression. Interestingly, after RpS21 levels reach their peak, there is a reduction in p-Mek and p-Erk (Fig5e, FigS4e) . This result is again consistent with RpS21 acting as a negative regulator of MAPK signaling. We note here that the timing of when RpS21 reached peak expression after serum stimulation varied from experiment to experiment and was influenced by cell type, but typically tracked with p-Mek and p-Erk levels (not shown). At later time points, both RpS21 and MAPK activity levels again rise (Fig5e, FigS4e) , which may reflect the known ability of MAPK signaling to oscillate 17, 46 . Collectively, these data support a model whereby RpS21 acts as both a negative regulator and effector of the MAPK pathway. However, as revealed in our genetic screen, this regulatory relationship preferentially manifests itself at low signal output levels (Fig5f).
DISCUSSION
Here, we revisit a well-proven strategy to identify Ras/MAPK modifiers (a haploinsufficiency screen in the Drosophila eye), but do so with the new angle of altering codon usage in a core signaling component to find signal strength-dependent regulators. We show here that changing codon usage in a signaling pathway component can be an effective strategy to find signal strength-dependent modifiers, as evidenced by our identification of 15 Df from a whole-genome screen that only modify the rough-eye phenotype driven by either a common or rare codonenriched Ras V12 transgene, but not both. From these efforts, we identify the RpS21 gene as a negative regulator of a weak or low-level Ras phenotype in the in vivo context of eye development.
We also provide evidence that the MAPK pathway can increase RpS21 expression, suggesting a potential negative feedback relationship between Ras/MAPK signaling and RpS21.
Our results show that altering codon usage can serve as a valuable platform to stably alter protein production to undertake signal strength-specific screens. Clearly, there are other ways that one can modulate signal output strength, such as modulating gene expression strength as we also do here. However, an advantage of altered codon usage is that it can be hard-wired into the genome, and thus no additional (and potentially confounding) experimental parameters such as altering temperature, inducing genes with drugs, etc. are required. Our approach should be applicable to any signal transduction pathway. The utility of our approach is underscored in the fact that signal strength-specific modifiers found in our screen appear to be enriched for genome regions not previously linked to Ras genetic modification. The causative genes contained within 14 of these differential Df hits remain to be mapped, and represent a potentially rich source of new genes modulating Ras/MAPK signaling. Intriguingly, these differential hits appear to be enriched in bHLH transcription factors. Of note, the bHLH transcription factor Myc is a well-known Erk target 47-50 , and it will be interesting to explore whether specific bHLH transcription factors are preferentially targeted by this pathway in signal strength-dependent contexts.
Given the importance of Ras/MAPK signaling in many settings across evolution, our identified modifiers may shed insight into how this pathway is controlled at different signal strengths. While our focus here is on Drosophila eye development, signal strength dependencies of the Ras/MAPK pathway are appreciated to play a role in human disease. Activating mutations in the MAPK pathway of humans underlie a class of human diseases termed RASopathies 51 . Further, relevant to our approach here, the weakest expressed mammalian RAS isoform, KRAS, is enriched in rare codons 23 and is the most commonly mutated RAS isoform in human cancers 52 . As such, modifiers of weak Ras signaling may provide a new class of proteins to explore in these diseases.
Our approach found that RpS21 functions as a negative regulator of low Ras/MAPK signaling. As Ras/MAPK signaling is known to drive tissue growth in diverse settings, this may suggest that RpS21 can function as a negative regulator of tissue or tumor growth. Interestingly, downregulation of RpS21 was previously shown to cause excessive hyperplasia in hematopoietic organs and imaginal disc overgrowth during larval development, suggesting RpS21 acts as tumor suppressor in Drosophila 39 . Although this finding may seem paradoxical given that ribosomal mutants in flies are well-known to cause "minute" phenotypes, characterized by short bristles, small body size, and delayed growth [53] [54] [55] [56] , a subset of ribosomal proteins including RpS21 have been identified to have a growth suppressive role 39, [57] [58] [59] [60] [61] , and our ribosomal candidate screen may have identified other such subunits. Further, haploinsufficiency of many ribosomal proteins is reported to be tumorigenic in zebrafish 62 , and heterozygous inactivating mutations of ribosomal proteins have been described in human cancers 63, 64 . Several mechanisms have been proposed to account for this apparent tumor suppressor activity of ribosome protein downregulation, including activation of p53 [65] [66] [67] , inhibition of NF-KB 68 , E2F 69 , MYC 70 , and CDK8 71 . Thus, RpS21 joins the ranks of an emerging number of ribosomal proteins with roles in growth suppression, although whether RpS21 acts as a tumor suppressor in mammals awaits investigation.
The mechanism underlying the negative regulation of Ras/MAPK signaling by RpS21 remains to be determined. In our work, we found that RpS21 downregulation promotes elevated levels of preferentially express subset of mRNA pools 76, 77 . Alternatively, RpS21 might participate in other cellular processes independent of its canonical ribosomal function, as has been shown for other ribosomal subunits [78] [79] [80] [81] . In contrast to our screen results revealing negative regulation by RpS21 in four different contexts, numerous ribosomal proteins (RpS21 included) were found among 1,162 genes to positively regulate Erk phosphorylation in a previous primary screen in cultured Drosophila S2R+ cells 14 . Unlike this Erk activation screen, we note that our Ras V12 eye modifier screen hits were not preferentially enriched for ribosomal subunits, and that ribosomes in general are not enriched among known FlyBase Ras genetic enhancers/suppressors. We hypothesize that the addition of insulin to the growth media, required for Erk activation in the context of the S2R+ cell screen, revealed a dependency for cell growth, which is dependent on both ribosomes and Erk activation. S2R+ cells have known differences from S2 cells in response to external signaling, and this could reflect differences in MAPK regulation in this context as well 82 , underscoring the need to understand signaling dynamics and regulation in a given biological context.
Finally, our work may have uncovered another layer in the increasingly appreciated negative feedback regulation of Ras/MAPK signaling 44 , one that preferentially operates at a low signal output threshold. Many negative regulators of Ras/MAPK signaling are involved in feedback loops and are conserved in Drosophila, C elegans, and humans 9, 43, [83] [84] [85] . In this regard, we present evidence that RpS21 not only suppresses Ras/MAPK signaling, but that Ras/MAPK signaling can stimulate RpS21 production. Future work can determine whether this elevation of RpS21 is a result of increased free (non-ribosomal) RpS21, or ribosomes in general. Nevertheless, our data may suggest the intriguing possibility that RpS21 is a negative regulator of the Ras/MAPK pathway as part of a negative feedback loop. Related to this, another question for future investigation is why RpS21/MAPK co-regulation is non-functional in contexts of heightened Ras/MAPK signaling, as we observed in S2 cells with high Ras/MAPK biochemical output, as well as at the phenotypic output level where Rps21/+ failed to noticeably modify the eye phenotype of Ras V12 Common. One possible explanation is that different MAPK signaling strengths activate a different host of MAPK targets, and this impacts the degree of negative regulation by RpS21. To that end, it will be important to further mine our screen to identify single gene modifiers in the other 14 Dfs, which may similarly yield new regulatory insight into the Ras/MAPK pathway.
METHODS
Generation of codon-altered Ras V12 genes in Drosophila
Codon-altered exon sequences for Ras V12 Common and Ras V12 Rare were created using the Kazusa codon usage database (https://www.kazusa.or.jp/codon/) and subsequently generated by 
Fly Genetics and Deficiency Screen
The Ras transgenes were combined with a sevGal4 driver and subsequently crossed to Df/Balancer flies. After 18-20 days, the rough eye phenotype of the resulting progeny was scored.
The scoring system was as follows (category=numerical score, qualitative description): Mild=1, no discoloration or necrotic tissue; Moderate=3, discoloration and no necrotic tissue; Severe=5, discoloration and necrotic tissue (see Fig1b,c). Severity scores for each genotype was calculated as follows: (#Mildx1+#Moderatex3+#Severex5)/Total # of flies. To determine if haploinsufficiency for a subset of genes altered the rough eye phenotype the following two genotypes for each deficiency (Df) were compared: Ras transgene only and Ras transgene + Df (used as an internal comparison to control for background effects). Then, we calculated a fold change score for both Ras V12 Common and Ras V12 Rare for each deficiency: Ras transgene + deficiency/Ras transgene.
For the primary screen, the fold change score was defined as follows: enhancer (fold change ≥1.35 or 5X more flies eclosed); suppressor (fold change ≤0.65 or 5X less flies eclosed). For the secondary screen, the fold change score was defined as follows: enhancer (fold change ≥1.95 or 5X more flies eclosed); suppressor (fold change ≤0.50 or 5X less flies eclosed). The final phenotype for a deficiency was defined as follows: not a modifier (neither Ras V12 Common or Ras V12 Rare + Df were modified); enhancer (both Ras V12 Common and Ras V12 Rare + Df were enhanced); suppressor (both Ras V12 Common and Ras V12 Rare + Df were enhanced); differential (only Ras V12 Common or Ras V12 Rare + Df were modified). Images of fly eyes were obtained using a Leica MZ10F microscope with a PlanApo 1.6X objective, Pixel Shift Camera DMC6200, and LASX software.
Protein Preparation and Analysis
All protein samples were prepared by homogenizing tissue on ice. For Fig1d, samples were processed in Laemmli buffer and then boiled for 5min. Samples were separated by 12% sodium dodecyl sulfate-polyacrylamide electrophoresis (SDS-PAGE) gels and transferred to an Odyssey nitrocellulose membrane (LI-COR Biosciences) for immunoblotting. The following antibodies were used: anti-FLAG M2 (1:500, Sigma, anti-mouse), anti-α-tubulin (1:20,000, Sigma, anti-mouse), IRDye 800CW (1:20,000, LI-COR Biosciences, anti-mouse). Signal was detected using LI-COR Odyssey CLx and analyzed using Image Studio (LI-COR Biosciences). For all other immunoblots, samples were processed in RIPA buffer containing 1% IGEPAL, 50mM NaCl, 2mM EDTA, 100mM Tris-HCl, pH 8.0, 0.1% Glycerol, 50 mM Naf, 10mM Na3VO4, and protease inhibitors (Roche). Drosophila heads and ovaries were collected and transferred to cold lyses to be homogenized with a pellet pestle. Lysates were incubated at 4 °C for 30 min on end-to-end rotator and then centrifuged at 21,000 x g for 10 min. The supernatant was transferred to a new tube.
Total protein was quantified using a BCA kit (Bio-Rad) and either 30 or 50 micrograms of protein was used for separation on either 12.5% or 15% gradient SDS-PAGE gels. Proteins on SDS gels were transferred onto polyvinylidene difluoride membranes. These membranes were probed with anti-Flag (Sigma, anti-mouse 1:1000), anti-Pan-Ras (Millipore, 1:50), anti-β-actin (Cell Signaling, 1:1000), anti-p-MEK1/2 (Cell Signaling, 1:500), anti-MEK1/2 (Cell Signaling, 1;500), anti-p-ERK1/2 (Cell Signaling, 1:1000), anti-ERK1/2 (Cell Signaling, 1:1000), anti-RpS21 (Abcam, 1:2000), anti-Pyo (anti-Glu-Glu, VWR, 1:500) primary antibodies in blocking buffer containing 5% milk followed by the secondary antibodies of goat anti-mouse IgG (H+L) HRP (Life Technologies, 1:10000) or goat anti-rabbit IgG (H+L) HRP (Thermo Fisher Scientific, 1:10000) . Immunoblots were visualized using Clarity Max TM ECL Western Blotting Detection Reagent (Bio-Rad) followed by exposure to digital acquisition using Chemi Doc Imager (Bio-Rad). For all blots, the contrast and/or brightness were altered equally across the entire image and then images were cropped for displaying as figures.
Cell Culture
KC and S2 cell lines were obtained from Bloomington (Indiana University DGRC Bloomington) and as a gift from Dr. David MacAlpine (Duke University) respectively. These cells were cultured in Schneider's Drosophila medium (Invitrogen) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin-L Glutamine (Invitrogen) at 25°C. FBS was heated for 60 minutes in 58°C and then cool down before added to medium. These cells were confirmed to be free of mycoplasma infection, as measured by the Duke Cell Culture Facility using MycoAlert PLUS test (Lonza). S2 and KC cell lines were stably transduced with the pMKInt-Hyg vector encoding Ras V12 Common and Ras V12 Rare cDNAs using 1000 ng of DNA in 6 well plates as instructed by Effectene transfection reagent (Qiagen). The following day, Schneider's media was changed, and cells were seeded in a coated culture dish (100x20 mm). Four days later, cells were passaged with fresh Schneider's medium and 200 µg/ ml hygromycin (Invitrogen) was added. The stably transfected cells were selected within a month growing in media containing hygromycin. Three days prior to any experiment, these cells were grown in media without hygromycin. Four million S2 cells that were stably transduced with Ras V12 Common and Ras V12 Rare plasmids were seeded into coated tissue culture dishes (60x15mm, VWR) with 2 ml of Schneider's media (without FBS).
Sixty micrograms of RpS21 dsRNA were added on top of these cells. One hour later, two ml Schneider's media containing 20% FBS were added on top of 2 ml Schneider's media without FBS resulting in medium with 10% FBS concentration in total media of this culture. hours after RNAi treatment, expression of Ras V12 Common and Ras V12 Rare transgenes were induced by CuSO4 for another 12 hours. Finally, these cells were collected 30-36 hours after dsRNA treatment. S2 cells were transiently transfected with either pMet-HA-Ras V12 , pMet-pyo-Raf ED , and pMet-myc-Mek EE vectors (kindly provided by Dr. Marc Therrien 15 ) using the Effectene transfection reagent as described above. Two days later, these cells were treated with 500 µM CuSO4 for 16 hours to include expression of transgene. KC cells Ras V12 Common and Ras V12 Rare were treated with 10 nM trametinib for 12-16 hours prior collecting for immunoblot assay.
dsRNA synthesis
S2 cell DNA was used to produce a PCR template for RpS21 dsRNA production using the forward primer "TAATACGACTCACTATAGGGTTACTGACCAGCCGATACCC" and reverse primer "TAATACGACTCACTATAGGGCCACGCTTAGAAGTTCCTGC". Next, 500 ng RpS21 PCR template was used for an in vitro production of dsRNA as instructed in the MEGAscrip T7 transcription kit (ThermoFisher). The dsRNA solution was cleared using MegaClear TM kit (ThermoFisher). Finally, the concentration of RpS21 dsRNA was measured and stored in -80°C for future use.
Gene enrichment analysis and statistical analyses
To determine the Codon Adaptive Index (CAI), sequences were entered at the CAIcal web-server 
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